Dexcom Inc
F:DC4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dexcom Inc
F:DC4
|
US |
|
L
|
Lockheed Martin Corp
F:LOM
|
US |
|
Regulus Resources Inc
XTSX:REG
|
CA |
|
CrediaBank SA
F:BCA0
|
GR |
|
Trane Technologies PLC
NYSE:TT
|
IE |
|
N
|
Nov Inc
XMUN:NO8
|
US |
|
C
|
Cannibble Foodtech Ltd
CNSX:PLCN
|
IL |
|
Decisive Dividend Corp
F:PC9
|
CA |
|
S
|
Samart Aviation Solutions PCL
SET:SAV
|
TH |
|
Schouw & Co A/S
F:5RF
|
DK |
|
P
|
Pasdec Holdings Bhd
KLSE:PASDEC
|
MY |
|
T
|
Telecom Argentina SA
BCBA:TECO2
|
AR |
|
DFDS A/S
F:29K
|
DK |
|
A
|
Avemio AG
DUS:3D6
|
DE |
|
G
|
Grupo Media Capital SGPS SA
XMUN:GQV
|
PT |
|
Asia Sejahtera Mina Tbk PT
IDX:AGAR
|
ID |
|
Nestle (Malaysia) Bhd
OTC:NSLYF
|
MY |
|
W
|
Wolford AG
DUS:WOF
|
AT |
|
Siam City Cement PCL
OTC:SICUF
|
TH |
Earnings Calls
Last Earnings Call
Revenue: Dexcom reported second-quarter revenue of $1.31 billion, up 13% year over year on a reported basis and 12% organically, with growth led by strong U.S. and international demand.
Guidance: Management raised full-year revenue guidance to $5.18 billion to $5.25 billion and also lifted gross margin, operating margin, and EBITDA margin targets.
Demand: New customer starts stayed at a record level globally, with a sequential uptick in the U.S. and broad-based strength across patient groups.
Coverage: The company said its CONNECT trial strengthens the case for broader reimbursement in non-insulin type 2 diabetes and that it has already submitted the data to CMS.
Products: Dexcom highlighted the launch of the redesigned Stelo app, progress on Smart Basal, the rollout of G7 15 Day, and Health Canada’s clearance of G7 15 Day.
Cash Return: Dexcom generated over $600 million of free cash flow in the first half and repurchased about $600 million of stock in Q2 under its $1 billion buyback plan.